Preferred Label : Raltegravir Potassium;

NCIt synonyms : N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[ (5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide Monopotassium Salt;

NCIt definition : The orally bioavailable potassium salt of a human immunodeficiency virus (HIV) integrase strand transfer inhibitor (HIV-1 INSTI) with HIV-1 antiviral activity. Raltegravir binds to and inhibits integrase, an HIV enzyme that inserts viral genetic material into the genetic material of the infected human cell. Inhibition of integrase prevents insertion of HIV DNA into the human DNA genome, thus blocking HIV replication.;

UNII : 43Y000U234;

InChIKey : IFUKBHBISRAZTF-UHFFFAOYSA-M;

CAS number : 871038-72-1;

Drug name : Isentress;

Chemical formula : C20H20FN6O5.K;

Details


Main resources

You can consult :


https://www.has-sante.fr/portail/jcms/c_2967178/fr/isentress
2019
true
France
French
adolescent
child
human immunodeficiency virus i infection
Raltegravir Potassium
drug therapy, combination
Raltegravir Potassium
Raltegravir Potassium
insurance, health, reimbursement
treatment outcome
administration, oral
raltegravir
adult
HIV integrase inhibitors
hiv infections
HIV-1
antiretroviral therapy, highly active
HIV integrase inhibitors
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_2580837/fr/isentress
http://www.has-sante.fr/portail/jcms/c_2580837/fr/isentress-100-mg-raltegravir-granules-pour-suspension-buvable-antiretroviral
2015
false
France
French
child
human immunodeficiency virus i infection
Raltegravir Potassium
drug therapy, combination
infant
infant, newborn
Raltegravir Potassium
Raltegravir Potassium
guidelines for drug use
insurance, health, reimbursement
treatment outcome
administration, oral
raltegravir
HIV integrase inhibitors
hiv infections
HIV-1
antiretroviral therapy, highly active
HIV integrase inhibitors
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_1776508/fr/isentress
http://www.has-sante.fr/portail/jcms/c_1701815/fr/isentress
http://www.has-sante.fr/portail/jcms/c_1702552/fr/isentress
http://www.has-sante.fr/portail/jcms/c_1001255/isentress
2014
false
France
French
adolescent
child
human immunodeficiency virus i infection
Raltegravir Potassium
drug therapy, combination
Raltegravir Potassium
Raltegravir Potassium
insurance, health, reimbursement
treatment outcome
administration, oral
raltegravir
adult
HIV integrase inhibitors
hiv infections
HIV-1
antiretroviral therapy, highly active
HIV integrase inhibitors
evaluation of the transparency committee

---
Nous contacter.
07/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.